HPIP Expression Predicts Chemoresistance and Poor Clinical Outcomes in Patients with epithelial ovarian cancer

This study aims to investigate the expression of HPIP, the Hematopoietic pre-B cell leukemia transcription factor (PBX)-interacting protein, and its association with platinum resistance in epithelial ovarian cancer (EOC). The protein expression of HPIP was analyzed by immunohistochemistry in 248 pat...

Full description

Saved in:
Bibliographic Details
Published in:Human pathology 2017-02, Vol.60, p.114-120
Main Authors: Wang, Yao, MD, Li, Mingxun, MD, Meng, Fanling, MD, PhD, Lou, Ge, MD, PhD
Format: Article
Language:English
Subjects:
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biomarkers, Tumor - analysis
Biomarkers, Tumor - blood
Biopsy
CA-125 Antigen - blood
Cancer therapies
Carcinoma, Ovarian Epithelial
Chemotherapy
Clinical outcomes
Confidence intervals
Disease-Free Survival
Drug resistance
Drug Resistance, Neoplasm
Epithelial ovarian cancer
Female
Gynecology
HPIP
Humans
Immunohistochemistry
Intracellular Signaling Peptides and Proteins - analysis
Kaplan-Meier Estimate
Leukemia
Lymphatic Metastasis
Lymphatic system
Medical prognosis
Membrane Proteins - blood
Metastasis
Middle Aged
Multivariate analysis
Neoplasm Grading
Neoplasm Staging
Neoplasms, Glandular and Epithelial - chemistry
Neoplasms, Glandular and Epithelial - drug therapy
Neoplasms, Glandular and Epithelial - pathology
Ovarian cancer
Ovarian Neoplasms - chemistry
Ovarian Neoplasms - drug therapy
Ovarian Neoplasms - pathology
Pathology
Platinum Compounds - therapeutic use
Platinum resistance
Predictive Value of Tests
Proportional Hazards Models
Proteins
Survival analysis
Time Factors
Treatment Outcome
Tumor Burden
Up-Regulation
Variables
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study aims to investigate the expression of HPIP, the Hematopoietic pre-B cell leukemia transcription factor (PBX)-interacting protein, and its association with platinum resistance in epithelial ovarian cancer (EOC). The protein expression of HPIP was analyzed by immunohistochemistry in 248 patients with EOC. Furthermore, we analyzed the association between HPIP expression and clinicopathological features including prognosis in EOC samples. High HPIP expression was correlated with platinum resistance in EOCs. HPIP in platinum-resistant cases was overexpressed compared with that in platinum-sensitive cases (P < .001). Platinum resistance was independently correlated with the International Federation of Gynecology and Obstetrics (FIGO) stage and HPIP overexpression. High HPIP expression was positively correlated with FIGO stage, histological grade, residual tumor size, lymph node metastasis, serum levels of CA125 and poor prognosis. Our findings indicate that HPIP overexpression is an independent predictor of platinum-based chemotherapy resistance and that it may also be a potential biomarker for targeted therapy.
ISSN:0046-8177
1532-8392
DOI:10.1016/j.humpath.2016.10.015